Oncocross Co., Ltd. develops drugs for the treatment of cancers, rare diseases, and intractable diseases in South Korea. Its products pipeline includes OC101 for liver cirrhosis; OC101+OC111 for non-alcoholic steatohepatitis; OC201+OC202e for Inhibition of cancer metastasis; OC211, a Pan-KRAS Inhibitor; OC221, an immuno-oncology combination; OC514 to treat amyotrophic lateral sclerosis and Duchenne muscular dystrophy; and OC701 to treat atopic dermatitis. The company is also developing OJP3101 for metabolic disease; OJP3101 for Cardiovascular Disease; ODP9401 for metabolic disease; and ODP2201, ODP2301, and ODP2401 to treat oncology-related diseases. It has a collaboration agreement with various pharmaceutical companies, research institutes, and bio-techs. The company was founded in 2015 and is based in Seoul, South Korea.
तुलना करने के लिए मीट्रिक्स | 382150 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध382150पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −13.0x | −11.9x | −0.6x | |
PEG अनुपात | 0.54 | −0.14 | 0.00 | |
क़ीमत/बुक | 6.8x | 4.0x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 122.9x | 13.2x | 3.4x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 8.9% | 44.8% | |
उचित मूल्य अपसाइड | अनलॉक करें | 3.3% | 6.6% | अनलॉक करें |